Roivant Sciences (ROIV) Non-Current Debt (2021 - 2024)
Roivant Sciences' (ROIV) quarterly Non-Current Debt came in at $311.7 million in Q2 2024, down 19.05% YoY from $385.1 million in Q3 2023, and down 27.61% on a QoQ basis from $430.6 million in Q1 2024.
Roivant Sciences (ROIV) Non-Current Debt (2021 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 4 years of Non-Current Debt data on file, last reported at $311.7 million in Q2 2024.
- Quarterly Non-Current Debt fell 19.05% year-over-year to $311.7 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $311.7 million (down 19.05% YoY) and the FY2024 annual result came in at $430.6 million, up 14.67% from the prior year.
- Non-Current Debt slipped to $311.7 million in Q2 2024, from $430.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $430.6 million in Q1 2024 to a low of $170.3 million in Q1 2021.
- A 4-year average of $314.4 million and a median of $375.3 million in 2022 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt surged 105.91% — and 2024, when it slipped 19.05%.
- Tracing ROIV's Non-Current Debt over 4 years: stood at $204.0 million in 2021, then jumped by 83.85% to $375.1 million in 2022, then climbed by 7.52% to $403.3 million in 2023, then retreated by 22.72% to $311.7 million in 2024.
- The last three Non-Current Debt figures came in at $311.7 million (Q2 2024), $430.6 million (Q1 2024), and $403.3 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 311.72 Mn |
| Mar 31, 2024 | 430.59 Mn |
| Dec 31, 2023 | 403.34 Mn |
| Sep 30, 2023 | 389.45 Mn |
| Jun 30, 2023 | 385.07 Mn |
| Mar 31, 2023 | 375.52 Mn |
| Dec 31, 2022 | 375.12 Mn |
| Sep 30, 2022 | 376.06 Mn |
| Jun 30, 2022 | 383.72 Mn |
| Mar 31, 2022 | 210.03 Mn |
| Dec 31, 2021 | 204.04 Mn |
| Sep 30, 2021 | 199.87 Mn |
| Jun 30, 2021 | 186.35 Mn |
| Mar 31, 2021 | 170.28 Mn |